BioCardia Inc banner

BioCardia Inc
NASDAQ:BCDA

Watchlist Manager
BioCardia Inc Logo
BioCardia Inc
NASDAQ:BCDA
Watchlist
Price: 1.26 USD 0.8% Market Closed
Market Cap: $13.4m

BioCardia Inc
Goodwill

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
|
See Also

BioCardia Inc
Goodwill Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Goodwill CAGR 3Y CAGR 5Y CAGR 10Y
BioCardia Inc
NASDAQ:BCDA
Goodwill
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Goodwill
$35.6B
CAGR 3-Years
4%
CAGR 5-Years
-4%
CAGR 10-Years
10%
Gilead Sciences Inc
NASDAQ:GILD
Goodwill
$8.3B
CAGR 3-Years
0%
CAGR 5-Years
15%
CAGR 10-Years
22%
Amgen Inc
NASDAQ:AMGN
Goodwill
$18.7B
CAGR 3-Years
6%
CAGR 5-Years
5%
CAGR 10-Years
2%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Goodwill
$1.5B
CAGR 3-Years
12%
CAGR 5-Years
9%
CAGR 10-Years
41%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Goodwill
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

BioCardia Inc
Glance View

Market Cap
13.4m USD
Industry
Biotechnology

BioCardia, Inc. operates as a clinical-stage regenerative medicine company. The company is headquartered in Sunnyvale, California and currently employs 28 full-time employees. The company is focused on developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases. Its lead therapeutic candidates are based on the CardiAMP Cell Therapy System, a platform which provides an autologous bone marrow-derived cell therapy for treatment in two clinical indications, such as ischemic heart failure and refractory angina resulting from chronic myocardial ischemia. Its second therapeutic platform is an investigational bone marrow derived allogeneic off-the shelf Neurokinin-1 Receptor Positive mesenchymal stem cell (MSC) therapy for the treatment of cardiac and pulmonary disease. The company has three enabling device product lines: the CardiAMP cell processing system, the Helix biotherapeutic delivery system (Helix), and the Morph vascular access product line (Morph). The company is advancing therapeutic candidates for heart failure, chronic myocardial infarction, and acute respiratory distress syndrome.

BCDA Intrinsic Value
0.002 USD
Overvaluation 100%
Intrinsic Value
Price

See Also

Back to Top